Marisa Gabriela Repetto

Dr. Marisa Gabriela Repetto

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1996 in Clinica Chimica Acta
Verified
Journal Article
Closed access
MRMarisa Gabriela Repetto
Marisa Gabriela Repetto
CRClaudia Reides
Claudia Reides
MCMaria L. Gomez Carretero
Maria L. Gomez Carretero
MCMarta Costa
Marta Costa
GGGloria Griemberg
Gloria Griemberg
SLSusana Llesuy
Susana Llesuy

12 December 2018 in Metallomics
Verified
Journal Article
Open access
PDF file
CSChristian Martín Saporito-Magriñá
Christian Martín Saporito-Magriñá
RMRosario Natalia Musacco-Sebio
Rosario Natalia Musacco-Sebio
GAGeoffroy Andrieux
Geoffroy Andrieux
LKLucas Kook
Lucas Kook
MOManuel Tomás Orrego
Manuel Tomás Orrego
MRMarisa Gabriela Repetto
Marisa Gabriela Repetto
Intracellular mechanisms of copper cytotoxicity.

20 November 2009 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
MRMarisa Gabriela Repetto
Marisa Gabriela Repetto
NFNidia F. Ferrarotti
Nidia F. Ferrarotti
ABAlberto Boveris
Alberto Boveris

1 February 2010 in Experimental and Molecular Pathology
Verified
Journal Article
Closed access
MRMarisa Gabriela Repetto
Marisa Gabriela Repetto
GOGeorgina Ossani
Georgina Ossani
AMAlberto J. Monserrat
Alberto J. Monserrat
ABAlberto Boveris
Alberto Boveris

1 January 2017 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
CSChristian Saporito-Magriñá
Christian Saporito-Magriñá
RMRosario Musacco-Sebio
Rosario Musacco-Sebio
JAJuan M. Acosta
Juan M. Acosta
SBSofía Bajicoff
Sofía Bajicoff
PPPaola Paredes-Fleitas
Paola Paredes-Fleitas
MRMarisa Gabriela Repetto
Marisa Gabriela Repetto

5 March 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CGClaudia Taborda Gómez
Claudia Taborda Gómez
FLFabiana Lairion
Fabiana Lairion
MRMarisa Gabriela Repetto
Marisa Gabriela Repetto
MEMiren Ettcheto
Miren Ettcheto
AMAmalia Merelli
Amalia Merelli
JAJeronimo Auzemdni
Jeronimo Auzemdni
Cannabidiol (CBD), a lipophilic cannabinoid compound without psychoactive effects, has emerged as adjuvant of anti-epileptic drugs (AEDs) in the treatment of refractory epilepsy (RE), decreasing the severity and/or frequency of seizures. CBD is considered a multitarget drug that could act throughout the canonical endocannabinoid receptors (CB1-CB2) or multiple non-canonical pathways. Despite the fact that the CBD mechanism in RE is still unknown, experiments carried out in our laboratory showed that CBD has an inhibitory role on P-glycoprotein excretory function, highly related to RE. Since CB2 is expressed mainly in the immune cells, we hypothesized that CBD treatment could alter the activity of polymorphonuclear neutrophils (PMNs) in a similar way that it does with microglia/macrophages and others circulating leukocytes. In vitro, CBD induced PMN cytoplasmatic vacuolization and proapoptotic nuclear condensation, associated with a significantly decreased viability in a concentration-dependent manner, while low CBD concentration decreased PMN viability in a time-dependent manner. At a functional level, CBD reduced the chemotaxis and oxygen consumption of PMNs related with superoxide anion production, while the singlet oxygen level was increased suggesting oxidative stress damage. These results are in line with the well-known CBD anti-inflammatory effect and support a potential immunosuppressor role on PMNs that could promote an eventual defenseless state during chronic treatment with CBD in RE.